The case for & against
Bull & Bear analysis
CooperCompanies, Inc. (NYSE: COO) is a leading player in the medical device sector, specializing primarily in contact lenses through its CooperVision segment and surgical instruments via CooperSurgical. The company has positioned itself well within the growing vision care and fertility markets, with a strong emphasis on innovative products, particularly in myopia control and silicone hydrogel lenses. As a recognized leader, CooperCompanies aims to leverage strategic operational efficiencies and shareholder returns amidst evolving market dynamics.
Bull says
- ↑Q2 revenue hit $1.08B (+8% YoY) with non-GAAP EPS $1.21 (+26% YoY).
- ↑Myopia control revenues rose 24% to $32M, driven by MyDay MySight.
- ↑Generated $96M FCF and repurchased $92M in stock this quarter.
- ↑Leadership in contact lenses and fertility supports sustained innovation.
- ↑Strong earnings yield and high book-to-price imply undervaluation.
- ↑Manageable leverage and solid institutional ownership boost financial stability.
Bear says
- ↓Negative growth and profitability factors alongside a $271.6M litigation charge.
- ↓Asia-Pacific demand softness, notably in Japan and China, slows sales.
- ↓Tariffs and raw-material cost increases pressuring margins going forward.
- ↓Future growth hinges on MyDay adoption; execution risk elevated.
- ↓Fertility segment growth forecast slowing to mid-single digits.
- ↓Weak momentum and high macro sensitivity heighten downside risks.
Investment themes with COO
Clinical instruments and devices powering patient care
Companies with strong ability to set prices
Earnings Call · Q2 2025 · Mgmt. Guidance
Transcript signals
Bull points
- 4%
- still remain an optimist about it
- 4%
Bear points
- $15,000, $20,000
- low single-digit grower
- low single digits